Impact of Ebola virus nucleoprotein on VP40 virus-like particle production: a computational approach.

Xiao Liu, Robert V Stahelin, Elsje Pienaar
Author Information
  1. Xiao Liu: Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA.
  2. Robert V Stahelin: Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA. ORCID
  3. Elsje Pienaar: Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA. epienaar@purdue.edu. ORCID

Abstract

Ebola virus (EBOV) matrix protein VP40 can assemble and bud as virus-like particles (VLPs) when expressed alone in mammalian cells. Nucleoprotein (NP) could be recruited to VLPs as inclusion body (IB) when co-expressed, and increase VLP production. However, the mechanism behind it remains unclear. Here, we use a computational approach to study NP-VP40 interactions. Our simulations indicate that NP may enhance VLP production through stabilizing VP40 filaments and accelerating the VLP budding step. Further, both the relative timing and amount of NP expression compared to VP40 are important for the effective production of IB-containing VLPs. We predict that relative NP/VP40 expression ratio and time are important for efficient production of IB-containing VLPs. We conclude that disrupting the expression timing and amount of NP and VP40 could provide new avenues to treat EBOV infection. This work provides quantitative insights into EBOV proteins interactions and how virion generation and drug efficacy could be influenced.

References

  1. Biophys J. 2012 Jun 6;102(11):2517-25 [PMID: 22713567]
  2. EMBO Rep. 2022 Nov 7;23(11):e51709 [PMID: 36094794]
  3. Virology. 2006 Jan 5;344(1):64-70 [PMID: 16364737]
  4. Future Virol. 2007 Mar;2(2):205-215 [PMID: 24093048]
  5. Sci Rep. 2017 Aug 9;7(1):7698 [PMID: 28794491]
  6. EBioMedicine. 2020 Feb;52:102601 [PMID: 31953031]
  7. J Biol Chem. 2022 Jul;298(7):102025 [PMID: 35568195]
  8. PLoS Pathog. 2016 Oct 18;12(10):e1005937 [PMID: 27755595]
  9. mBio. 2019 Jul 23;10(4): [PMID: 31337716]
  10. Virol J. 2006 May 23;3:31 [PMID: 16719918]
  11. J Virol. 2012 Nov;86(21):11779-88 [PMID: 22915810]
  12. Sci Rep. 2017 Feb 27;7:43144 [PMID: 28240256]
  13. Protein Cell. 2015 May;6(5):351-62 [PMID: 25910597]
  14. Virology. 1985 Nov;147(1):169-76 [PMID: 4060597]
  15. Protein Cell. 2022 Feb;13(2):120-140 [PMID: 33141416]
  16. J Gen Virol. 2010 Jun;91(Pt 6):1478-83 [PMID: 20164259]
  17. J Biol Chem. 2013 Feb 22;288(8):5779-89 [PMID: 23297401]
  18. PLoS One. 2018 Aug 2;13(8):e0201827 [PMID: 30071116]
  19. PLoS Med. 2016 Apr 19;13(4):e1001997 [PMID: 27093560]
  20. J Virol. 2004 Jul;78(14):7344-51 [PMID: 15220407]
  21. Nature. 2021 Aug;596(7872):410-416 [PMID: 34252919]
  22. Am J Nurs. 2021 Apr 1;121(4):22 [PMID: 33755619]
  23. Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14402-7 [PMID: 23940347]
  24. Int J Mol Sci. 2022 Feb 22;23(5): [PMID: 35269550]
  25. Glob Health Sci Pract. 2020 Jun 30;8(2):178-182 [PMID: 32430358]
  26. N Engl J Med. 2021 Feb 4;384(5):403-416 [PMID: 33378609]
  27. Trends Microbiol. 2007 Sep;15(9):408-16 [PMID: 17698361]
  28. Microbiol Spectr. 2024 Apr 2;12(4):e0309823 [PMID: 38407984]
  29. PLoS Pathog. 2006 Sep;2(9):e99 [PMID: 17009868]
  30. Mol Cancer. 2021 Feb 16;20(1):33 [PMID: 33593376]
  31. Clin Infect Dis. 2015 Aug 15;61(4):496-502 [PMID: 25904375]
  32. J Virol. 2007 Apr;81(7):3554-62 [PMID: 17229682]
  33. Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1075-1080 [PMID: 29339477]
  34. Curr Opin Immunol. 2020 Aug;65:14-20 [PMID: 32244193]
  35. Drugs. 2021 Jan;81(1):175-178 [PMID: 33432551]
  36. J Infect Dis. 2014 Aug 15;210(4):558-66 [PMID: 24526742]
  37. Adv Healthc Mater. 2021 Apr;10(7):e2001650 [PMID: 33506607]
  38. Microbiol Mol Biol Rev. 2018 Mar 28;82(2): [PMID: 29592895]
  39. J Virol. 2017 Oct 27;91(22): [PMID: 28878087]
  40. PLoS One. 2012;7(1):e29608 [PMID: 22247782]

Grants

  1. UM1TR004402/U.S. Department of Health & Human Services | National Institutes of Health (NIH)
  2. AI081077/U.S. Department of Health & Human Services | National Institutes of Health (NIH)

MeSH Term

Ebolavirus
Viral Core Proteins
Humans
Virion
Nucleoproteins
Viral Matrix Proteins
Hemorrhagic Fever, Ebola

Chemicals

nucleoprotein VP40, Ebola virus
Viral Core Proteins
Nucleoproteins
VP40 protein, virus
Viral Matrix Proteins

Word Cloud

Created with Highcharts 10.0.0VP40VLPsNPproductionEBOVVLPexpressionEbolavirusvirus-likecomputationalapproachinteractionsrelativetimingamountimportantIB-containingmatrixproteincanassemblebudparticlesexpressedalonemammaliancellsNucleoproteinrecruitedinclusionbodyIBco-expressedincreaseHowevermechanismbehindremainsunclearusestudyNP-VP40simulationsindicatemayenhancestabilizingfilamentsacceleratingbuddingstepcomparedeffectivepredictNP/VP40ratiotimeefficientconcludedisruptingprovidenewavenuestreatinfectionworkprovidesquantitativeinsightsproteinsviriongenerationdrugefficacyinfluencedImpactnucleoproteinparticleproduction:

Similar Articles

Cited By